Skip to main content
Industry News
FDA clears Athenex's IND application for T-cell therapy
9/24/2020

The FDA has cleared Athenex's investigational new drug application for its autologous T cell receptor-T cell therapy TCRT-ESO-A2, which targets NY-ESO-1 positive solid tumors in human leukocyte antigen-A positive patients.

Full Story: